{"ok":true,"entity":{"id":"hikma-pharmaceuticals","name":"Hikma Pharmaceuticals PLC","entityType":"company","officialName":"Hikma Pharmaceuticals PLC","canonicalName":"Hikma Pharmaceuticals PLC","displayName":"Hikma Pharmaceuticals PLC","category":"注射剤・ブランドジェネリック・ジェネリック医薬品の多国籍製薬企業","shortDescription":"Hikma Pharmaceuticals PLCは、英国に本社を置き、ロンドン証券取引所（LSE：HIK）などに上場する多国籍の製薬企業で、Injectables、Branded、Hikma Rxの3事業を展開します。2026年8月6日発表の2026年上期決算では、売上高17億2,800万ドル（4%増）、コア営業利益4億500万ドル（9%増）で、Said DarwazahがChief Executive Officerを務めています。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.hikma.com/","updatedAt":"2026-10-22T11:50:32.298Z","secondaryClusters":[],"alias":["Hikma","ヒクマ"],"searchKeywords":["Hikma","Hikma Pharmaceuticals","ヒクマ","ヒクマ・ファーマシューティカルズ","注射剤","ジェネリック医薬品","MENA 製薬","HIK"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}